PreveCeutical Medical Inc.: PreveCeutical Provides Corporate Update
Vancouver, British Columbia (Newsfile Corp. - May 31, 2021) -
PreveCeutical Medical Inc. (the Company or PreveCeutical ) (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is pleased to provide the following update.
The Company s highest priority is to create shareholder value through the development and commercialization of products and delivery technology.
The Company has partnered with UniQuest Pty Limited and the University of Queensland through its Australian subsidiary, PreveCeutical (Australia) Pty Ltd, to conduct research and development. The Company is very pleased with the positive outcome from the successful completion of the following programs:
Stabilization of Blue Scorpion Venom was completed in October 2019.